Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 2/20 | 0.36 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6487982 | 0.89 | DCTPP1 (0.41) | DCTPP1PIK3C2B | |
| SCHEMBL6487661 | 0.87 | PDE2A (0.43) | PDE2AELANE | |
| SCHEMBL6490261 | 0.87 | CYP1A2 (0.42) | PDE2A | |
| SCHEMBL6488639 | 0.77 | TARBP2 (0.47) | TP53HPGD | |
| SCHEMBL6488966 | 0.77 | RXRA (0.41) | DCTPP1PIK3C2BTP53 | |
| SCHEMBL6503273 | 0.77 | CYP1A2 (0.42) | PDE2AHPGD | |
| SCHEMBL6496733 | 0.76 | ALOX5AP (0.47) | DCTPP1PIK3C2B | |
| SCHEMBL6490645 | 0.76 | PTGDR (0.44) | DCTPP1PIK3C2BHPGD | |
| SCHEMBL6498502 | 0.76 | ALOX5AP (0.37) | DCTPP1PIK3C2B | |
| SCHEMBL6498192 | 0.76 | RXRA (0.43) | TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | PDE2A 1017/4885DCTPP1 1534/4885SYK 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.